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Abstract: Clinical effectiveness of imatinib mesylate in cancer treatment is compromised by 
its off-target cardiotoxicity. In the present study, we have developed physically stable imatinib 
mesylate-loaded poly(lactide-co-glycolide) nanoparticles (INPs) that could sustainably release 
the drug, and studied its efficacy by in vitro anticancer and in vivo cardiotoxicity assays. MTT 
(methylthiazolyldiphenyl-tetrazolium bromide) assay revealed that INPs are more cytotoxic 
to MCF-7 breast cancer cells compared to the equivalent concentration of free imatinib mesy-
late. Wistar rats orally administered with 50 mg/kg INPs for 28 days showed no significant 
cardiotoxicity or associated changes. Whereas, increased alanine aminotransferase, aspartate 
aminotransferase, and alkaline phosphatase levels, and reduced white blood cell, red blood cell, 
and hemoglobin content were observed in the animals administered with free drug. While the 
histological sections from hearts of animals that received INPs did not show any significant 
cardiotoxic symptoms, loss of normal architecture and increased cytoplasmic vacuolization were 
observed in the heart sections of animals administered with free imatinib mesylate. Based on 
these results, we conclude that nano-encapsulation of imatinib mesylate increases its efficacy 
against cancer cells, with almost no cardiotoxicity.
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Introduction
Overexpression of receptor tyrosine kinase is a common mechanism associated with 
multiple malignancies.1 Imatinib mesylate is a tyrosine kinase inhibitor, which typi-
cally blocks the tyrosine kinase activity of BCR-Abl,2 platelet-derived growth factor 
receptors (PDGFRs),3 and KIT4 proteins, forming the basis of its use in the treatment 
of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GISTs). 
In CML, the characteristic reciprocal translocation between chromosomes results in 
the derivative Philadelphia chromosome, with the BCR-Abl fusion gene that pro-
duces the BCR-Abl hybrid protein, possessing constitutive tyrosine kinase activity. 
Imatinib mesylate is used to inhibit BCR-Abl from phosphorylating other proteins 
that are involved in the pathogenesis of CML.5,6 In the case of GISTs, the underlying 
mechanism is a gain-of-function mutation in c-kit or PDGFRα genes, causing the 
production of abnormal KIT and PDGFRα receptors that induce uncontrolled cell 
growth and cell division. Imatinib mesylate specifically antagonizes the intracellular 
adenosine triphosphate (ATP)-binding sites of these receptors, making it a leading 
drug in the treatment of GISTs.7
BCR-Abl hybrid protein only exists in cancer cells and not in healthy cells. 
However, KIT and PDGFR are also expressed in normal cells, where they perform 
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crucial roles in hematopoiesis, blood vessel formation, 
and vasculature maintenance.8,9 PDGFRs are also known 
to be involved in the response of endothelial and smooth 
muscle cells to injury and other stressors in the cardiovas-
cular system.10 In this context, employing a tyrosine kinase 
inhibitor like imatinib mesylate to treat cancer has been 
reported to cause unanticipated cardiotoxicity.11–14 For 
instance, imatinib mesylate-treated male spontaneously 
hypertensive rats are reported to present cardiac lesions, 
characterized by cytoplasmic vacuolization and myofibril-
lar loss, suggesting a correlation between hypertension and 
imatinib mesylate-induced cardiotoxicity.12 More recently, 
the deleterious effect of imatinib mesylate on the heart 
was shown to be dose-, time-, and age-dependent.14 These 
authors found mitochondrial impairment and cell death 
as the mechanisms of myocyte loss and cardiac dysfunc-
tion, which is further exacerbated in an aging population. 
Since the therapeutic value of imatinib mesylate is limited 
by such off-target cardiotoxicity, alternative strategies 
such as nanoformulations are necessary to overcome this 
problem.
Drug-encapsulated nanoparticles with sustained release 
properties have been attempted to minimize off-target toxicity 
of many cancer drugs,15–20 including imatinib mesylate.21–23 
While the nano-encapsulation of imatinib mesylate improves 
its antitumor activity,23,24 it is also demonstrated to minimize 
the cytotoxicity of the drug to normal cells.21,22 Moreover, 
poly(lactide-co-glycolide) (PLGA) microspheres containing 
imatinib mesylate inhibited craniopharyngioma-mediated angio-
genesis24 and intracranial xenograft glioma growth.25,26 However, 
there is no report on the evaluation of cardiotoxicity of imatinib 
mesylate-loaded nanoparticles so far. Hence, in the current 
investigation, we have developed and characterized imatinib 
mesylate-loaded PLGA nanoparticles (INPs) and have evaluated 
their in vitro cytotoxicity against cancer cells and cardiac toxicity 
in Wistar rats, in comparison with the free drug.
Materials and methods
Chemicals and reagents
Imatinib mesylate was obtained from Ranbaxy Pharmaceuti-
cals (Delhi, India). PLGA (acid-terminated; lactide:glycolide 
50:50; Mw [molecular weight] 24,000–38,000 D), polyvinyl 
alcohol (PVA; Mw 31,000–50,000 D), methylthiazolyldiphe-
nyl-tetrazolium bromide (MTT), dimethylformamide (DMF), 
and coumarin-6 were purchased from Sigma-Aldrich Co, 
St Louis, MO, USA. Sodium hydroxide, phosphate buffer, 
potassium dihydrogen phosphate, methanol, and acetone used 
in the current study were acquired from Merck Millipore, 
Billerica, MA, USA. All reagents used in the present study 
were of analytical grade.
Preparation and characterization 
of nanoparticles
Preparation
INPs were prepared by emulsion solvent evaporation 
method.18 Briefly, 100 mg PLGA and imatinib mesylate 
(5 mg) were dissolved in 5 mL of chloroform. This solution 
was added drop by drop to the 20 mL aqueous phase con-
taining 1.5% PVA and homogenized at 18,000 rpm (IKA T 
25 Ultra Turrax® homogenizer). After homogenization, the 
nano-emulsion was stirred for 3 hours. The resulting emul-
sion was centrifuged at 20,000 rpm for 15 minutes to pellet 
down the nanoparticles. The pellet was washed three times 
with ultra-pure water to remove any free drug. Then, the pel-
let was freeze-dried and stored at 4°C until further use.
Particle size, shape, encapsulation efficiency, 
and drug content
Particle size distribution, mean particle size, and zeta poten-
tial of INPs were determined in a Zetasizer by dynamic light 
scattering and laser Doppler anemometry (Zetasizer Nano 
ZS; Malvern Instruments, Malvern, UK). Briefly, 500 μg of 
INPs was suspended in 1 mL of deionized water. An electric 
field of 150 mV was applied to observe the electrophoretic 
velocity of the particles. All measurements were made at 
room temperature.
The content of imatinib mesylate in INPs was measured by 
spectrophotometric assay. Briefly, 10 mg INPs was dissolved 
in 1 mL of dichloromethane and 2 mL phosphate-buffered 
saline (PBS). The solution was centrifuged at 10,000 rpm, 
and the supernatant was collected. Absorbance at 265 nm 
was read in a spectrophotometer (Shimadzu UV-1700) using 
PBS as a blank to determine the drug content from a standard 
graph.27 The percentage of encapsulation efficiency (EE%) 
and drug content (DC%) of INPs was determined using the 
following two formulas:
 EE%
Weight of encapsulated drug
Weight of drug used
= ×100  (1)
 DC%
Weight of encapsulated drug
Weight of nanoparticles
= ×100  (2)
Scanning electron microscopy (SEM) characterized the 
INPs morphologically. Samples were prepared by dropping 
INP onto aluminum stubs and allowing them to air-dry. 
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The air-dried particles were coated with gold in vacuum 
using a Fiscon Instrument SC 502 sputter coater and then 
observed under the SEM (Leica Cambridge S 360; Leica 
Microsystems, Wetzlar, Germany).
In vitro drug release of nanoparticles
The in vitro drug release of INPs was carried out using the 
previously described method with some modifications.28 
Briefly, 10 mg of INPs was suspended in 2 mL PBS and trans-
ferred into a dialysis bag. The dialysis bag was then placed 
into a 100 mL bottle containing 50 mL PBS and was stirred at 
100 rpm at 37°C. While stirring, 1 mL PBS sample was with-
drawn at different time points from the bottle for 10 days. To 
maintain the volume, 1 mL PBS was added to the bottle after 
each withdrawal. Drug content of each sample was measured 
spectrophotometrically, as mentioned in the “Particle size, 
shape, encapsulation efficiency, and drug content” section.
In vitro cytotoxicity studies
Cancer cell line culture
Human breast cancer cell line MCF-7 was used in the pres-
ent study. Cells were maintained in Roswell Park Memorial 
Institute (RPMI) 1640 medium supplemented with 10% fetal 
bovine serum (FBS), 100 U/mL penicillin, and 100 μg/mL 
streptomycin (Thermo Fisher Scientific, Waltham, MA, 
USA) at 37°C in a 5% CO
2
 humidified incubator.
MTT assay
The effect of imatinib mesylate in the form of free drug 
solution and INPs on cell proliferation was determined using 
MTT assay. MCF-7 cells were plated in flat-bottom 96-well 
plates at 5,000 cells per well. After incubation for 24 hours 
at 37°C, the culture medium was removed and replaced with 
100 μL fresh medium containing free drug (0.148, 0.295, 
0.59, and 1.18 μg), and INPs (6.56, 13.11, 26.22, and 52.44 
μg); both free drug and INP additions were equivalent to final 
imatinib concentrations of 2.5, 5, 10, and 20 μM, respec-
tively. Corresponding controls were maintained by adding 
100 μL medium for free drug control and 100 μL medium 
containing 52.44 μg empty nanoparticles for INP control. 
After 48 hours, medium from the treatments and controls 
were replaced with 100 μL medium containing 50 μg 
MTT and were incubated for 1 hour. Then, 100 μL sodium 
dodecyl sulfate (SDS) solution (20% w/v, water:DMF at a 
1:1 ratio, pH 4.7) was added to each well and further incu-
bated for 24 hours to dissolve the formazan crystals formed. 
The absorbance was read at 570 nm in an enzyme-linked 
immunosorbent assay (ELISA) plate reader (Victor 1420; 
PerkinElmer Inc, Waltham, MA, USA). The amount of MTT 
that is converted to formazan after incubation with cells cor-
responds to the number of viable cells. The half-maximal 
inhibitory concentration (IC
50
) was determined by nonlinear 
regression analysis.
Cellular uptake of nanoparticles
In vitro cellular uptake of nanoparticles was studied using 
curcumin-loaded PLGA nanoparticles (CNPs). These 
nanoparticles were prepared essentially as mentioned in the 
“Preparation and characterization of nanoparticles” section, 
but using curcumin in the place of imatinib mesylate. MCF-7 
cells were seeded in an 8-well ibiTreat microscopy chamber 
(Ibidi GmbH, Munich, Germany) and allowed to attach and 
grow. After 24 hours, 150 μL medium containing 100 μg/mL 
CNPs was added to the cells. After 90 minutes, cells were 
washed, and were replaced with fresh medium. To track the 
uptake of nanoparticles, the lysosomes of MCF-7 cells were 
stained with the LysoTracker® Red probe and analyzed under 
confocal microscope (Axiovert 135M; Zeiss International, 
Oberkochen, Germany).
Subacute toxicity analyses
Animals and treatments
Subacute toxicity of INPs was evaluated in Wister rats weigh-
ing about 130–150 g. This study was approved by the Animal 
Ethical Committee, Padmavathi College of Pharmacy, Tamil 
Nadu, India. Animals were divided into three groups (group 1, 
group 2, and group 3), each group containing six adult 
females. Group 1 received 2 ml PBS and was treated as a 
control. Group 2 received 2222 mg/kg INPs (equivalent to 
50 mg/kg imatinib) suspended in PBS. Group 3 received 
50 mg/kg free drug. Treatment for each group was done 
each day at 9 am, and was done per orally (PO) for 28 days. 
Throughout the study period, animals were monitored for the 
development of any toxicological signs and symptoms such 
as abnormal posture, abnormal movements, difficulties in 
respiration, and changes in body weight and feed intake.
Hematology and biochemistry
To know the potential side effects at the cellular level, blood 
biochemistry and hematological parameters were examined 
in treated groups of animals and compared with the control 
group. Blood and serum samples for hematological and 
biochemical studies were collected from the orbital sinus of 
each animal in vials rinsed with heparin and vials contain-
ing ethylenediaminetetraacetic acid (EDTA), respectively. 
Hematological analyses include white blood cells (WBCs), 
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red blood cells (RBCs), and hemoglobin (Hb) content. 
The serum samples were analyzed for aspartate aminotrans-
ferase (AST), alanine aminotransferase (ALT), and alkaline 
phosphatase (ALP) to determine possible indication of 
myocardial damage, if any. All analyses were carried out in 
a smart lab batch analyzer.
Cardiotoxicity
Hearts of control and treated animals were collected and 
observed for gross pathological and weight changes on 
day 29. For histopathology, heart tissue preserved in 
10% formalin was embedded in paraffin using standard 
procedures. Sections of 4 μm thickness were obtained in 
a microtome and mounted on glass slides using standard 
techniques. After staining with hematoxylin and eosin, the 
slides were examined under a light microscope equipped 
with photography. Photomicrographs were analyzed for 
myocardial architecture.
Statistical analysis
Data were analyzed using GraphPad Prism 5 software 
(GraphPad Software, Inc, La Jolla, CA, USA). Results are 
expressed as the mean values ± standard deviation (SD). 
Statistical significance between treatments was analyzed by 
Student’s t-test. IC
50
 values were determined by nonlinear 
curve fitting of log concentration versus cell viability.
Results and discussion
Characterization of INPs
We have nano-encapsulated imatinib mesylate within 
the biodegradable, US Food and Drug Administration 
(FDA)-approved PLGA polymer.5 Moreover, PLGA 
nano-encapsulation is known to reduce the subacute toxicity, 
including cardiotoxicity of doxorubicin and erlotinib.17,18
Particle size distribution
Nanoparticle size is one of the most important characteristics, 
as it regulates the biological fate, toxicity, targeting ability, 
as well as drug loading, drug release, and stability of the 
formulation.29 Particle size distribution of the INPs is shown 
in Figure 1. The average diameter of INPs ranged between 
250 and 300 nm, with a polydispersity index of 0.20. Zeta 
potential is an important characteristic for nanoparticles, as 
surface charge directly controls the aggregation behavior of 
the particles. The lowest zeta potential (-10.6 mV) indicated 
that the INPs were physically stable.
Shape of nanoparticles
A SEM image of INPs is shown in Figure 2. From the results, 
it is clear that the nanoparticles have a smooth spherical 
shape. Their smooth surface reveals the complete removal 
of solvent from the formulated nanoparticles, indicating their 
good quality.30
Encapsulation efficiency, drug content, and in vitro 
drug release
The encapsulation efficiency of the nanoparticles was found 
to be 89.94%. The drug content of the nanoparticles was 
2.25% (0.0225 mg/mg INPs).
As graphically illustrated in Figure 3, the release of imatinib 
mesylate from the INPs occurred in a biphasic manner, with an 
initial burst phase followed by a diffusion-controlled slower 
release phase, as previously reported.25 Soon after 6 hours and 
48 hours, about 40% and 60% of the encapsulated drug was 
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Figure 1 Histogram showing the particle size and size distribution of INPs.
Abbreviation: INPs, imatinib mesylate-loaded poly(lactide-co-glycolide) nanoparticles.
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released, respectively, and this initial burst can be attributed 
to the drug molecules adhering to the nanoparticle surface. As 
the hydrophilicity of PLGA nanoparticles enables an extensive 
water penetration to the polymeric matrix, a significant amount 
of drug release happens during the initial days of incubation 
in aqueous buffer. The initial burst was followed by a gradual 
rise and reached 70% on day 10, indicating a sustained release 
phase. Similar in vitro release kinetics of fluorescein isothio-
cyanate-loaded polyethylene glycol–PLGA nanoparticles, eg, 
approximately 40% on day 1 and a sustained release over the 
next 28 days has been previously demonstrated.21
Internalization of nanoparticles by cancer 
cells
Fluorescent images of MCF-7 cells co-incubated with CNPs 
for 90 minutes and stained with LysoTracker Red taken 
under red filter (Figure 4A) and green filter (Figure 4B), 
respectively, show the localization of lysosomes and CNPs. 
The merged image (Figure 4C) clearly shows that the CNPs 
are colocalized within the lysosomes, indicating their inter-
nalization by endocytosis.
Cytotoxicity of imatinib mesylate 
in the form of free drug and INPs
MTT-based cell proliferation assay results of MCF-7 cells 
revealed that cell viability was reduced with increasing 
concentrations of INPs or free drug (Figure 5). However, 
INPs consistently showed higher viability reduction than 
equivalent free drug in all the concentrations tested. 
No cytotoxicity was observed in cells treated with just 
medium (free drug control) and empty nanoparticles (INP 
control). The IC
50
 value for INPs was found to be 2.6 μM at 
48 hours, which was 2.9 times less than imatinib mesylate 
solution.
In vivo toxicity study
The results of hematological, biochemical, and heart weight 
analyses of rats administered with imatinib mesylate in the 
form of free drug (50 mg/kg) and INPs (2.222 g/kg) are 
summarized in Table 1.
Hematology
Although the WBC, RBC, and Hb content were reduced both 
in the nanodrug- and free drug-treated animals compared to 
the control group, the changes were not statistically signifi-
cant for INPs. However, there was a significant decrease in 
the WBC, RBC, and Hb count of free drug-treated animals 
(Table 1), indicating the development of anemia and reduc-
tion of immunity in these animals.
Biochemistry
ALT, AST, and ALP are liberated into the blood after exten-
sive tissue injury; in particular, elevated levels of AST are 
associated with heart muscle injury.31 Biochemical analysis 
of AST, ALT, and ALP levels in the serum samples did not 
show any significant change between control and nanodrug 
treated groups. Nevertheless, an increased level of these 
enzymes was observed in the animals administered with 
free drug compared to control (Table 1), indicating tissue 
damage, including myocardial damage.
Heart weight
Heart weight was significantly increased due to heart 
inflammation in free drug-treated animals over INP-treated 
Figure 2 Scanning electron microscopic image of INPs (scale bar =2 μm).
Abbreviation: INPs, imatinib mesylate-loaded poly(lactide-co-glycolide) nanopar-
ticles.
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Figure 3 In vitro drug release characteristics of INPs, showing a biphasic profile, an 
initial burst release up to 24 hours, and then an extended release over 10 days.
Abbreviations: INPs, imatinib mesylate-loaded poly(lactide-co-glycolide) nano-
particles.
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animals and control animals. However, no significant change 
was noticed between INP-treated and control animals 
(Table 1).
Cardiac histopathology
Histopathological analysis of heart sections from INP- 
administered animals (Figure 6C and D) revealed no sig-
nificant toxicity-related changes compared to the controls 
(Figure 6A and B). This is in agreement with the fact 
that nano-encapsulation reduces drug-induced off-target 
cardiotoxicity of many drugs such as doxorubicin15,20 and 
epirubicin.19 In addition, nano-encapsulation also improves 
the drug’s antitumor activity17 by making the tumor cells 
more sensitive to the drug.16 In this line of research, using 
CML stem cells, Palamà et al have reported that packaging 
of imatinib mesylate into a biodegradable carrier based on 
polyelectrolyte microcapsules increased the drug’s retention 
effects and antitumor activity, while improving the ex vivo 
purging of malignant progenitors from patient autografts.24 
Both the reduction in off-target cardiotoxicity and increased 
antitumor activity could be attributed to the gradual release 
of imatinib mesylate, or reduced exposure of imatinib 
mesylate to the heart tissue, as it is encapsulated inside the 
nanoparticles.32
In the case of rats administered with free imatinib mesylate, 
loss of normal architecture and damage to cardiac muscle 
fibers were observed (Figure 6E and F), which is consistent 
with its previously reported semi-targeting property and heart 
toxicity,13,33 even at low concentrations.12 Imatinib mesylate-
caused cardiotoxicity manifests cardiac mitochondrial 
dysfunction, ventricular dysfunction, and mild myocardial 
lesions.21,34
Conclusion
In spite of many reports on nanoformulations of anticancer 
drugs, very few studies are available on the in vivo toxicity 
of nanoparticles. Here, we have demonstrated that PLGA 
Figure 4 Internalization of CNPs. 
Notes: (A) Red fluorescence from LysoTracker® Red showing lysosomes and acidic vesicles; (B) green fluorescence from curcumin showing intracellular localization 
of CNPs; (C) overlap image of both figures (A and B) resulted in yellow spots showing that CNPs are in the lysosomes, and acidic vesicles of mature endosomes. 
Abbreviation: CNPs, curcumin-loaded poly(lactide-co-glycolide) nanoparticles.
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Figure 5 MTT assay results showing higher cytotoxicity of INPs compared to free 
imatinib mesylate. Imatinib concentration of 0.0 μM represents respective controls 
of INPs and free drug, which showed 100% cell viability.
Abbreviations: INPs, imatinib mesylate-loaded poly(lactide-co-glycolide) nano-
particles; MTT, methylthiazolyldiphenyl-tetrazolium bromide.
Table 1 Subacute in vivo toxicity analyses of rats after 28 days
Parameters Control INPs Free drug
WBCs (109/L) 11.49±0.20 11.35±0.23 10.43±1.02*
RBCs (1012/L) 7.36±0.35 7.06±0.36 6.38±0.88*
Hb (g/L) 12.81±0.51 12.22±1.19 11.06±0.81**
AST (U/L) 118.50±4.54 121.66±2.80 129.83±2.13***
ALT (U/L) 51.08±2.37 52.33±1.86 58.50±3.39**
ALP (U/L) 111.66±3.20 111.33±3.32 118.66±4.63*
Heart weight (g) 0.66±0.02 0.65±0.01 0.71±0.04*
Notes: Statistically significant differences from controls (*P0.05; **P0.01; 
***P0.001), using Student’s t-test. Data are presented as mean ± SD of three 
replications.
Abbreviations: SD, standard deviation; INPs, imatinib mesylate-loaded poly(lactide-
co-glycolide) nanoparticles; WBCs, white blood cells; RBCs, red blood cells; 
Hb, hemoglobin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; 
ALP, alkaline phosphatase.
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nano-encapsulation significantly reduces drug-induced 
cardiotoxicity of imatinib mesylate. Likewise, erlotinib-, 
epirubicin-, and doxorubicin-induced cardiotoxicity have 
also been significantly reduced by nano-encapsulation of 
these drugs with PLGA or polyethylene glycol–PLGA.17–19,35 
Extensive studies in terms of acute and chronic toxicity, 
and pharmacokinetic and pharmacodynamic effects of ima-
tinib mesylate are necessary to understand the mechanisms 
behind the reduced cardiac toxicity and the long-term effects 
of INPs.
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Figure 6 Histopathology of myocardium from experimental animals. Representative images of left ventricular histology from experimental animals stained with hematoxylin 
and eosin are shown. 
Notes: (A, B) The cardiac myofibrils from control rats exhibited regular arrangement of thick and thin myofilaments. (C, D) INP treatment did not alter the morphology 
of myocardium of rats significantly, although very few isolated vacuoles are present. (E, F) Myofibrillar loss and formation of variable-sized cytoplasmic vacuoles in the 
myocardium of rats treated with 50 mg/kg dose of free imatinib mesylate. Vacuole structures are indicated with black arrows.
Abbreviation: INP, imatinib mesylate-loaded poly(lactide-co-glycolide) nanoparticle.
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